Red Light Therapy for Alzheimer's & Dementia

Alzheimer’s disease affects roughly 900,000 people in the UK and over 55 million worldwide. Current pharmaceutical treatments offer modest symptomatic relief at best. Against this backdrop, transcranial photobiomodulation (tPBM) — the application of red and near-infrared light to the brain through the skull — has emerged as a genuinely promising area of research. The evidence is still early-stage, but several well-designed studies suggest real therapeutic potential.

This guide reviews the published research, explains the proposed mechanisms, and provides practical protocol guidance for those considering tPBM for cognitive decline.

What Is Transcranial Photobiomodulation (tPBM)?

Transcranial PBM involves applying near-infrared light (typically 810 nm) to the scalp with the aim of delivering photon energy to the cerebral cortex. The light penetrates the skull — approximately 2-3% of surface irradiance reaches the brain at 810 nm, according to a 2016 study by Tedford et al. (PMID: 27267860). While this sounds like a small fraction, it is sufficient to trigger measurable biological effects.

The primary target is cytochrome c oxidase (CCO), the terminal enzyme in the mitochondrial electron transport chain. In Alzheimer’s disease, mitochondrial dysfunction is a well-established pathological feature. CCO activity is reduced in affected brain regions, contributing to impaired energy metabolism, increased reactive oxygen species (ROS), and neuronal death.

How tPBM May Help in Alzheimer’s Disease

The proposed mechanisms are supported by both preclinical and clinical evidence:

1. Mitochondrial Rescue

Alzheimer’s neurons show impaired mitochondrial function. By stimulating CCO, tPBM increases ATP production and restores cellular energy metabolism. A 2018 study by Gonzalez-Lima and Barrett demonstrated that tPBM at 1064 nm improved CCO activity and cognitive performance in healthy adults (PMID: 24568233), establishing proof of principle for mitochondrial stimulation through the skull.

2. Reduction of Amyloid-Beta

Amyloid-beta (Aβ) plaques are a hallmark of Alzheimer’s pathology. Preclinical studies have shown that PBM reduces Aβ burden in transgenic mouse models. De Taboada et al. (2011) demonstrated that 808 nm laser treatment delivered transcranially three times per week for six months significantly reduced Aβ plaque load, decreased brain amyloid levels, and improved cognitive performance in APP/PS1 transgenic mice (PMID: 22035540). The effect was associated with reduced inflammation and increased ATP synthesis.

Purushothuman et al. (2014) replicated these findings using 670 nm light, showing reduced Aβ plaques, neurofibrillary tangles, and oxidative stress markers in a different transgenic mouse model (PMID: 25505230).

3. Anti-Inflammatory Effects

Neuroinflammation — driven by microglial activation and pro-inflammatory cytokine release — is a major contributor to Alzheimer’s progression. PBM has been shown to shift microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. A 2017 study by Song et al. demonstrated that 810 nm PBM reduced TNF-α, IL-1β, and IL-6 levels in the brains of Aβ-injected mice, with corresponding improvements in memory task performance (PMID: 28525894).

4. Increased Cerebral Blood Flow

tPBM increases nitric oxide (NO) production, which vasodilates cerebral blood vessels. Reduced cerebral blood flow is an early feature of Alzheimer’s disease, often preceding clinical symptoms by years. A 2019 study by Hipskind et al. demonstrated that tPBM improved cerebral perfusion in patients with chronic traumatic brain injury (PMID: 30346890), a condition that shares vascular pathology with Alzheimer’s.

5. Neurogenesis and Synaptic Support

Preclinical evidence suggests PBM upregulates brain-derived neurotrophic factor (BDNF) and promotes hippocampal neurogenesis. Xuan et al. (2015) showed that 810 nm PBM increased BDNF expression and neuroprogenitor cell proliferation in mice following traumatic brain injury (PMID: 25196192). While TBI and Alzheimer’s are distinct conditions, the neurotrophic mechanisms are relevant to both.

Key Human Studies

The Saltmarche Case Series (2017)

One of the most-cited studies in this space is the case series by Saltmarche et al., published in Photomedicine and Laser Surgery (PMID: 28186867). Five patients with mild to moderate Alzheimer’s disease received tPBM using a 810 nm intranasal device combined with transcranial LED clusters, administered daily for 12 weeks.

Results:

Significant improvements in MMSE (Mini-Mental State Examination) scores
Improved sleep quality and reduced anxiety
Caregivers reported better functional status and reduced behavioural disturbances
Effects were sustained during the treatment period but declined when treatment was paused

Limitations: This was a small case series with no control group. However, the consistency of improvement across all five patients — and the deterioration upon treatment withdrawal — is noteworthy for a progressive neurodegenerative disease.

The Berman Study (2017)

Berman et al. published a case report of a single patient with moderate Alzheimer’s who received tPBM at 810 nm for 28 consecutive days (PMID: 28186869). The patient showed improvements in cognitive testing, reduced agitation, and better sleep. Improvements were noted by week two and continued through the treatment period.

The Chao (2019) Pilot RCT

Chao published a pilot randomised controlled trial examining tPBM in dementia patients (PMID: 31379757). Using an 810 nm LED helmet, participants received 12 weeks of home-based treatment. The active group showed trends toward improvement on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) compared to sham, though the study was underpowered to reach statistical significance. Importantly, no adverse events were reported.

The Liebert Study (2021)

Liebert et al. conducted a randomised, sham-controlled trial of tPBM in patients with dementia, using an 810 nm LED device applied to the head and body (PMID: 34255712). Over 12 weeks, the active treatment group showed significant improvements in ADAS-cog scores, MMSE scores, and functional assessments compared to sham. This is one of the strongest RCTs to date, though the sample size was still relatively small (n=18 active, n=18 sham).

The Nizamutdinov Study (2021)

Nizamutdinov et al. reported on tPBM in patients with Alzheimer’s disease using 1060-1080 nm wavelength and a novel gamma-frequency pulsed protocol at 40 Hz (PMID: 34050033). The rationale for 40 Hz stimulation is based on research by Tsai et al. (2016), which showed that 40 Hz gamma entrainment reduced Aβ in mouse models (PMID: 27929004). The combined approach — NIR light pulsed at gamma frequency — improved cognitive scores and reduced brain atrophy as measured by MRI.

The De Taboada Contribution

Luis De Taboada’s preclinical work deserves special attention. As the primary inventor of the transcranial laser technology used in several stroke and TBI clinical trials, De Taboada established that 808 nm laser light could penetrate the human skull at therapeutically relevant levels and produce measurable neuroprotective effects.

His 2011 mouse study (PMID: 22035540) remains the most comprehensive preclinical demonstration of tPBM effects on Alzheimer’s pathology. The study showed:

40% reduction in Aβ plaque number
52% reduction in Aβ plaque area
Reduced levels of inflammatory markers
Improved performance on Morris water maze testing
Enhanced ATP levels in brain tissue

These findings provided the scientific foundation for the subsequent human trials described above.

Connection to Parkinson’s Disease

The mitochondrial dysfunction targeted by tPBM is also a central feature of Parkinson’s disease. Several studies have examined PBM for Parkinson’s, including a notable trial by Hamilton et al. (2019) using a 670 nm and 810 nm helmet device (PMID: 30993063). Improvements in gait, fine motor skills, and cognitive function were reported.

The overlap between Alzheimer’s and Parkinson’s pathology — both involve mitochondrial dysfunction, neuroinflammation, and protein aggregation — suggests that tPBM may have broad neuroprotective properties. See our guide on brain fog and cognitive function for related evidence.

Practical Protocol for tPBM

Based on the published literature, the following protocol represents a synthesis of the parameters used in positive human studies:

Wavelength

810 nm is the most-studied wavelength for tPBM in dementia. It offers optimal skull penetration and targets the peak absorption band of cytochrome c oxidase. Wavelengths of 1060-1080 nm have also shown promise, particularly when pulsed at 40 Hz.

Dose

Irradiance at scalp surface: 25-50 mW/cm²
Treatment time per site: 3-6 minutes
Fluence per site: 10-30 J/cm²
Estimated brain dose: 0.3-1.0 J/cm² (accounting for skull attenuation)

Treatment Areas

Target the following regions for maximal cortical coverage:

Bilateral prefrontal cortex — forehead, 2-3 cm above the eyebrows
Bilateral temporal cortex — above and in front of the ears
Posterior parietal cortex — top of the head, posterior
Occipital region — base of the skull

Some protocols also include intranasal application, which delivers light to the ventral brain surface via the cribriform plate.

Frequency

Treatment sessions: Daily or 5 days per week
Minimum duration: 8-12 weeks before assessing response
Pulsing: 40 Hz pulsing may enhance gamma-entrainment effects (based on Nizamutdinov et al.)

Device Options

For home-based tPBM, devices with the following specifications are suitable:

810 nm LEDs with adequate power density (minimum 25 mW/cm² at scalp surface)
Helmet or cluster-style devices that cover multiple treatment areas simultaneously
Intranasal clips (810 nm) for supplementary brain irradiation

Full-body panels positioned near the head are not ideal for tPBM because the light must penetrate directly through the skull; scattered photons from a distant panel do not achieve sufficient fluence at the cortex.

What to Expect

Based on the published case studies and trials, improvements may include:

Better scores on cognitive assessments (MMSE, ADAS-cog)
Improved sleep quality
Reduced agitation and anxiety
Better functional independence in daily activities
Slowed rate of cognitive decline (rather than complete reversal)

Most positive studies report initial improvements within 4-8 weeks, with continued benefit over 12+ weeks of treatment. Critically, several studies noted that improvements declined when treatment was stopped, suggesting that ongoing treatment is necessary to maintain benefits.

Caregiver Considerations

For most Alzheimer’s patients, tPBM will be administered or supervised by a caregiver. Practical considerations include:

Setting Up a Home Protocol

Choose a helmet-style device that the patient can wear without needing to hold it in position. Handheld devices require sustained positioning that may be difficult for patients with motor impairment or agitation.
Establish a consistent routine. Administer tPBM at the same time each day, ideally during a calm period. Many caregivers report that mid-morning works well, after breakfast but before any sundowning behaviour begins.
Keep sessions short and comfortable. If a patient shows agitation or resistance, shorten the session rather than forcing a full treatment. Some benefit is better than no benefit.
Combine with other activities. Some patients tolerate tPBM better while listening to familiar music or sitting with a caregiver. The helmet can be worn during quiet activities.

Tracking Progress

Measuring cognitive outcomes at home is challenging but important:

Use the MMSE or MoCA if a healthcare provider can administer it at baseline and at 4-week intervals
Keep a daily log of sleep quality, mood, agitation episodes, and functional abilities (dressing, feeding, conversation coherence)
Ask multiple caregivers to contribute observations — subtle changes may be noticed by someone who sees the patient less frequently

Combining with Conventional Treatment

tPBM should be used alongside, not instead of, prescribed medications (cholinesterase inhibitors, memantine). There are no known interactions between PBM and standard Alzheimer’s medications. The therapies target different mechanisms and may be complementary.

Non-pharmacological approaches that can be combined with tPBM include:

Physical exercise (shown to support neuroplasticity and cerebral blood flow)
Cognitive stimulation therapy (CST)
Mediterranean-style diet (anti-inflammatory nutritional support)
Social engagement and structured activities

Limitations and Caveats

It is important to set realistic expectations:

Sample sizes are small. The largest RCT to date had 36 participants. Large-scale, multi-centre trials are needed.
No cure. tPBM does not reverse Alzheimer’s disease. The evidence suggests it may slow progression and improve symptoms.
Publication bias. Positive results are more likely to be published. Null findings may exist in unpublished trials.
Dose uncertainty. Skull thickness, hair density, and scalp melanin content all affect the dose reaching the brain. Individual variation is significant.
Regulatory status. tPBM is not an approved treatment for Alzheimer’s in any jurisdiction. It is considered investigational.

Safety

tPBM has an excellent safety profile across all published studies. No serious adverse events have been reported. Mild, transient effects include:

Slight warmth at treatment sites
Temporary tingling or headache (rare)
Mild sleep changes during the first week of treatment

Contraindications include active brain tumours, epilepsy triggered by light stimulation, and concurrent use of photosensitising medications. Patients on anticoagulants should consult their doctor before starting tPBM.

The Bottom Line

Transcranial photobiomodulation for Alzheimer’s disease is one of the most exciting areas in PBM research. The preclinical evidence — particularly De Taboada’s work showing reduced amyloid burden and improved cognition in transgenic mice — is compelling. Human studies, whilst small, have consistently shown improvements in cognitive function, sleep, and behaviour with excellent safety profiles.

The field needs larger, well-controlled RCTs to establish definitive efficacy. But for a condition with limited treatment options, tPBM represents a low-risk intervention with genuine mechanistic rationale and encouraging clinical signals. For individuals with early-to-moderate Alzheimer’s or their caregivers considering tPBM, the published evidence supports cautious optimism — provided expectations are realistic and the therapy is used alongside, not instead of, conventional medical care.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Alzheimer’s disease requires professional medical management. Consult a neurologist or specialist before starting any new therapy.